Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China

References

• Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19–27. doi:10.1097/j.pain.0000000000001384
   PubMed Web of Science ®Google Scholar
• Wang JL, Zhang WJ, Luo WJ, et al. Investigation on the status quo of patients in pain department in some areas based on ICD-11 chronic pain classification. Chin J Pain Med. 2019;25(4):267–275.
   Google Scholar
• Yamamoto PA, Conchon Costa AC, Lauretti GR, et al. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice. Pharmacogenomics. 2019;20(13):971–982. doi:10.2217/pgs-2019-0066
   PubMed Web of Science ®Google Scholar
• Rogers M, Tang L, Madge DJ, et al. The role of sodium channels in neuropathic pain. Semin Cell Dev Biol. 2006;17(5):571–581. doi:10.1016/j.semcdb.2006.10.009
   PubMed Web of Science ®Google Scholar
• Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J Pain. 2006;7(Suppl 1):S38–47. doi:10.1016/j.jpain.2005.09.008
   PubMed Web of Science ®Google Scholar
• Skerratt SE, West CW. Ion channel therapeutics for pain. Channels. 2015;9(6):344–351. doi:10.1080/19336950.2015.1075105
   PubMed Web of Science ®Google Scholar
• De Logu F, Geppetti P. Ion channel pharmacology for pain modulation. Handb Exp Pharmacol. 2019;260:161–186.
   PubMedGoogle Scholar
• Bell DC, Dallas ML. Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia. Br J Pharmacol. 2018;175(12):2312–2321. doi:10.1111/bph.13916
   PubMed Web of Science ®Google Scholar
• Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states--maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011;25(2):141–154. doi:10.1016/j.berh.2011.02.005
   PubMed Web of Science ®Google Scholar
• Tang XP, Jing YL. Observation on the prevention of chronic pain symptoms with sodium ion channel blockers. Chin J Clin Rehabil. 2005;36:190–192.
   Google Scholar
• Chen HL, Zhou LL, Hu L, et al. Research progress of neurophysiological mechanism of chronic pain. Chongqing Med. 2021;50(10):1777–1781.
   Google Scholar
• Adams DJ, Berecki G. Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels. Biochim Biophys Acta. 2013;1828(7):1619–1628. doi:10.1016/j.bbamem.2013.01.019
   PubMed Web of Science ®Google Scholar
• Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120(6):1315–1334. doi:10.1016/j.bja.2018.02.066
   PubMed Web of Science ®Google Scholar
• Xu L, Ding X, Wang T, et al. Voltage-gated sodium channels: structures, functions, and molecular modeling. Drug Discovery Today. 2019;24(7):1389–1397. doi:10.1016/j.drudis.2019.05.014
   PubMed Web of Science ®Google Scholar
• Hodgkin AL, Huxley AF. Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo. J Physiol. 1952;116(4):449–472. doi:10.1113/jphysiol.1952.sp004717
   PubMed Web of Science ®Google Scholar
• Nassar MA, Levato A, Stirling LC, et al. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain. 2005;1:24. doi:10.1186/1744-8069-1-24
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD, Waxman SG. Diversity of composition and function of sodium channels in peripheral sensory neurons. Pain. 2015;156(12):2406–2407. doi:10.1097/j.pain.0000000000000353
   PubMed Web of Science ®Google Scholar
• Yu SY, Wan Y, Wan Q, et al. Chinese expert consensus on the diagnosis and treatment of postherpetic neuralgia. Chin J Pain Med. 2016;22(03):161–167.
   Google Scholar
• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662. doi:10.1016/j.pain.2013.11.013
   PubMed Web of Science ®Google Scholar
• Stanos SP. Topical agents for the management of muscul oskeletal pain. J Pain Symptom Manage. 2007;33(3):342–355. doi:10.1016/j.jpainsymman.2006.11.005
   PubMed Web of Science ®Google Scholar
• Zhu Q, Fan B, Zhang D, et al. Chinese expert consensus on diagnosis and treatment of peripheral neuropathic pain. Chin J Pain Med. 2020;26(5):321–328.
   Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Wang SL, Wang H, Nie HY, et al. The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: a meta-analysis. Medicine. 2017;96(51):e9167. doi:10.1097/MD.0000000000009167
   PubMed Web of Science ®Google Scholar
• Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2014;80(5):556–567.
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663–1676. doi:10.1185/03007990903047880
   PubMed Web of Science ®Google Scholar
• Jun M, Lijun H. Effect of nerve block combined with lidocaine gel patch on postherpetic neuralgia. Chin J Med Clin. 2019;21(01):66–68.
   Google Scholar
• Wu YS, Fu JM, Dong JJ, et al. Clinical efficacy and safety of pregabalin combined with carbamazepine in the treatment of postherpetic neuralgia. Medical Theory and Practice. 2016;29(24):3326–3328.
   Google Scholar
• Joharchi K, Memari M, Azargashb E, et al. Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. J Diabetes Metab Disord. 2019;18(2):575–582. doi:10.1007/s40200-019-00427-w
   PubMed Web of Science ®Google Scholar
• Devi P, Madhu K, Ganapathy B, et al. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012;44(1):51–56. doi:10.4103/0253-7613.91867
   PubMed Web of Science ®Google Scholar
• Deng CH. Clinical effect of carbamazepine on diabetic painful neuropathy. Mod Diagno Ther. 2014;25(14):3234–3236.
   Google Scholar
• Jiang J, Li Y, Shen Q, et al. Effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer: a randomized controlled trial. J Clin Oncol. 2019;37(2):135–143. doi:10.1200/JCO.18.00896
   PubMed Web of Science ®Google Scholar
• Tsai JH, Liu IT, Su PF, et al. Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. BMC Palliat Care. 2023;22(1):4. doi:10.1186/s12904-023-01126-3
   PubMed Web of Science ®Google Scholar
• Li F, Ni JX, Wu BS, et al. Clinical study of bulleyaconitine A assisted to morphine sulfate sustained-release tablets in the treatment of mid-late cancer pain. J Changchun Univ Chin Med. 2014;30(3):460–462. doi:10.1007/s11802-014-2123-6
   Google Scholar
• Olesen SS, Bouwense SA, Wilder-Smith OH, et al. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141(2):536–543. doi:10.1053/j.gastro.2011.04.003
   PubMed Web of Science ®Google Scholar
• Expert consensus on diagnosis and treatment of diabetic peripheral neuropathic pain. Chin J Pain Med. 2018;24(08):561–567.
   Google Scholar
• Ziegler D. Painful Diabetic Neuropathy. Diabetes Care. 2009;32(Suppl 2):s414–9. doi:10.2337/dc09-S350
   PubMedGoogle Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354. doi:10.1097/00002508-200211000-00002
   PubMed Web of Science ®Google Scholar
• Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain normal glucose tolerance: the MONICA/ KORA Augsburg Surveys S2. Pain Med. 2009;10(2):393–400. doi:10.1111/j.1526-4637.2008.00555.x
   PubMed Web of Science ®Google Scholar
• Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021;17(7):400–420. doi:10.1038/s41574-021-00496-z
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350. doi:10.1056/NEJMoa032782
   PubMed Web of Science ®Google Scholar
• Sadosky A, Mardekian J, Parsons B, et al. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–217. doi:10.1016/j.jdiacomp.2014.10.013
   PubMed Web of Science ®Google Scholar
• Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ. 2014;348:g1799. doi:10.1136/bmj.g1799
   PubMedGoogle Scholar
• Diabetes Society of Chinese Medical Association. Expert consensus on diagnosis and treatment of diabetic neuropathy (2021). Chin J Diabetes. 2021;13(6):540–557.
   Google Scholar
• Wolffff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306. doi:10.4414/smw.2010.12995
   PubMed Web of Science ®Google Scholar
• Li FX. Acupoint injection of bulleyaconitine A in the treatment of diabetic peripheral neuropathy. Chin Med Sci Technol Press. 1999;3:101–102.
   Google Scholar
• Feng Y, Xu JJ, Lin XQ, et al. Chronic postoperative or post-traumatic pain. Chin J Pain Med. 2021;27(04):241–245.
   Google Scholar
• Coccolini F, Corradi F, Sartelli M, et al. Postoperative pain management in non-traumatic emergency general surgery: WSES-GAIS-SIAARTI-AAST guidelines. World J Emerg Surg. 2022;17(1):50. doi:10.1186/s13017-022-00455-7
   PubMed Web of Science ®Google Scholar
• Aubrun F, Nouette-Gaulain K, Fletcher D, et al. Revision of expert panel’s guidelines on postoperative pain management. Anaesth Crit Care Pain Med. 2019;38(4):405–411. doi:10.1016/j.accpm.2019.02.011
   PubMed Web of Science ®Google Scholar
• Xu JG. Expert consensus on postoperative pain management in adults. J Clin Anesthesiol. 2017;33(09):911–917.
   Google Scholar
• Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg. 2012;115(2):428–442. doi:10.1213/ANE.0b013e318249d36e
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015;114(1):10–31. doi:10.1093/bja/aeu293
   PubMed Web of Science ®Google Scholar
• Chinese Association of Pain Physicians, Medical Cluster for Pain Disorders, Beijing Center for Quality Control and Improvement of Pain Management. Expert Consensus on pharmacotherapy for chronic musculoskeletal pain (2018). Chin J Pain Med. 2018;24(12):881–887.
   Google Scholar
• Briggs AM, Woolf AD, Karsten D, et al. Reducing the global burden of musculoskeletal conditions. Bulletin of the World Health Organization. 2018;96(5):366–368. doi:10.2471/BLT.17.204891
   PubMed Web of Science ®Google Scholar
• Chinese Aging Well Association. Expert consensus on diagnosis and treatment of musculoskeletal chronic pain. Orthopedics. 2021;12(05):389–395.
   Google Scholar
• Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206–219. doi:10.1016/j.genhosppsych.2008.12.006
   PubMed Web of Science ®Google Scholar
• Liu YQ, Ding XN, Wang YD. Clinical study on the treatment of common chronic pain with bulleyaconitine A tablets. Chin J Pain Med. 2011;17(5):314–315.
   Google Scholar
• Zhang YC, Yang QR, He Y, et al. Clinical observation on the treatment of osteoarthritis and rheumatoid joint with bulleyaconitine A. Pharmacol Clin Chin Med. 2000;16(2):43–45.
   Google Scholar
• Xu N, Liu R, Zang JJ, et al. Efficacy and safety evaluation of bulleyaconitine A tablets in the treatment of osteoarthritis. ChinMed. 2014;9(8):1170–1173.
   Google Scholar
• Wang YS, By LIU, Ah Z, et al. Clinical observation of 35 cases of rheumatoid arthritis treated with bulleyaconitine A capsules. Hunan J of Trad Chin Med. 2009;25(1):6–8.
   Google Scholar
• Du N, Zhu D. Effect of bulleyaconitine A tablets combined with Tripterygium wilfordis tablets on knee osteoarthritis. J Henan Univ. 2015;34(1):50–52.
   Google Scholar
• National Administration of Traditional Chinese Medicine, National Health Commission of the People’s Republic of China. Cancer pain diagnosis and treatment code (2018). Clin Educ Gener Pract. 2019;17(01):4–8.
   Google Scholar
• Fallon M, Giusti R, Aielli F, Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl):4.
   Google Scholar
• Qin WJ, Ren XY, Li R, et al. Expert consensus on cancer pain management. Chin J Pain Med. 2019;25(11):801–807.
   Google Scholar
• Fallon M, Giusti R, Aielli F, et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–iv191. doi:10.1093/annonc/mdy152
   PubMed Web of Science ®Google Scholar
• Smith LE, Murphy BA, Smith DK. Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. Support Care Cancer. 2023;31(4):221. doi:10.1007/s00520-023-07683-w
   PubMed Web of Science ®Google Scholar
• Zhang H, Sun Y, Xu GY. New progress in pathologic mechanism and clinical treatment of chronic visceral pain. Chin J Pain Med. 2017;23(01):2–20.
   Google Scholar
• Olesen AE, Farmer AD, Olesen SS, et al. Management of chronic visceral pain. Pain Manag. 2016;6(5):469–486. doi:10.2217/pmt-2015-0011
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(10):981–988. doi:10.1111/j.1365-2036.2005.02685.x
   PubMed Web of Science ®Google Scholar
• Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218–1225. doi:10.1136/gut.2006.110858
   PubMed Web of Science ®Google Scholar
• Olesen SS, Graversen C, Bouwense SA, et al. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS One. 2013;8(3):e57963. doi:10.1371/journal.pone.0057963
   PubMed Web of Science ®Google Scholar
• Huang S. Study on the anti-visceral pain and anti-anxiety effect of monoponitine. Shang Jiao Tong Univ. 2019;2:4.
   Google Scholar
• Huang SN, Wei J, Huang LT, et al. Bulleyaconitine A inhibits visceral nociception and spinal synaptic plasticity through stimulation of microglial release of dynorphin A. Neural Plast. 2020;2020:1484087. doi:10.1155/2020/1484087
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574–581. doi:10.1002/cpt.1004
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017;12(12):CD007963. doi:10.1002/14651858.CD007963.pub3
   PubMedGoogle Scholar
• Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–335. doi:10.1155/2014/754693
   PubMed Web of Science ®Google Scholar
• Xiao H, Ma K, Huang D, et al. Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain. World J Clin Cases. 2021;9(9):2100–2109. doi:10.12998/wjcc.v9.i9.2100
   PubMed Web of Science ®Google Scholar
• McGeeney BE. Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents. J Pain Symptom Manage. 2009;38(2 Suppl):S15–27. doi:10.1016/j.jpainsymman.2009.05.003
   PubMed Web of Science ®Google Scholar
• Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):CD007076. doi:10.1002/14651858.CD007076.pub3
   PubMed Web of Science ®Google Scholar
• Lee JE, Min KR, Kim SH, et al. Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital. Yonsei Med J. 2020;61(10):875–879. doi:10.3349/ymj.2020.61.10.875
   PubMed Web of Science ®Google Scholar
• Johnson KD, Miller LN, Pouliot JD, et al. Retrospective analysis of oxcarbazepine in pregnant women with substance use disorders: focus on safety. J Pharm Pract. 2021;34(1):28–34.
   PubMed Web of Science ®Google Scholar